The payment recipient is the government
Signal Diagnostics agreed to pay the United States $20.5 million, the Justice Department announced September 30. The settlement resolves False Claims Act allegations about retaining overpayments from the HRSA COVID-19 uninsured testing program. It does not announce a cash-claim route for all patients tested by the laboratory.
The government alleges Signal submitted testing and specimen-collection claims for people who had health insurance and later identified ineligible claims through an internal audit. The described retention period runs January 2022 through May 2023, following claims submitted October 2020 through March 2022.
An enforcement settlement is not a consumer claim form
The distinction is who was paid and who should have repaid the program. A settlement about federal reimbursement does not itself prove a patient bill was invalid or that the patient is owed a share of the headline amount. Individual billing disputes need their own records and review.
The Justice Department describes allegations resolved through the settlement, not a consumer refund program with an application deadline. Readers should not send personal information to an invented claim portal. Keep actual lab and insurance documents if checking a separate bill; the government recovery is not automatic patient compensation.